Data Presented at American Academy of Dermatology Shows Significant Improvement in Moderate-to-Severe Nail Psoriasis with No New Safety Signals PRINCETON, N.J., March 7, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries, Inc., USA, a wholly owned subsidiary of Sun Pharmaceutical...
Hence then, the article about ilumya tildrakizumab asmn found effective for treatment of moderate to severe plaque psoriasis affecting nails in study presented at 2025 aad conference was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( ILUMYA® (tildrakizumab-asmn) Found Effective for Treatment of Moderate-to-Severe Plaque Psoriasis Affecting Nails in Study Presented at 2025 AAD Conference )
Also on site :
- My Daughter’s Friend Has a Crush on My Husband. It’s Making Us Both Deeply Uncomfortable.
- Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline
- Maga’s biggest fear is coming true and Trump won’t survive it